Grace Therapeutics, Inc.
GRCEDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
15dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How GRCE's past catalysts played out
GTX-104
Aneurysmal Subarachnoid Hemorrhage (aSAH)
CaPre
Hypertriglyceridemia
Lipid Lowering Medication
Hypertriglyceridemia
CaPre (TM)
Hypertriglyceridemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GTX-104 | Phase 3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | - | - |
CaPre | Phase 3 | Hypertriglyceridemia | - | - |
Lipid Lowering Medication | Phase 2 | Hypertriglyceridemia | - | - |
CaPre (TM) | Phase 2 | Hypertriglyceridemia | - | - |
Hypertriglyceridemia
2 drugs in this indication
Aneurysmal Subarachnoid Hemorrhage (aSAH)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Grace Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Grace Therapeutics, Inc.'s (GRCE) pipeline across Phase 3, Phase 2. Its lead program is GTX-104 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Grace Therapeutics, Inc.'s next FDA catalyst?→
Grace Therapeutics, Inc.'s (GRCE) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GRCE biotech catalysts?→
Add GRCE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Grace Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.